Personalized dosimetry for a deeper understanding of metastatic response to high activity
131I-mIBG high activity therapy
Dosimetry
dose-response correlation
high risk neuroblastoma
Journal
Quantitative imaging in medicine and surgery
ISSN: 2223-4292
Titre abrégé: Quant Imaging Med Surg
Pays: China
ID NLM: 101577942
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
21
05
2021
accepted:
06
09
2021
entrez:
3
2
2022
pubmed:
4
2
2022
medline:
4
2
2022
Statut:
ppublish
Résumé
Dosimetry in molecular radiotherapy for personalized treatment is assuming a central role in clinical management of aggressive/relapsed tumors. Relapsed/refractory metastatic high-risk neuroblastoma (rrmHR-NBL) has a poor prognosis and high-activity Fourteen patients affected by rrmHR-NBL were treated with high-activity The cumulative Our experience demonstrated feasibility of high activity therapy of
Sections du résumé
BACKGROUND
BACKGROUND
Dosimetry in molecular radiotherapy for personalized treatment is assuming a central role in clinical management of aggressive/relapsed tumors. Relapsed/refractory metastatic high-risk neuroblastoma (rrmHR-NBL) has a poor prognosis and high-activity
METHODS
METHODS
Fourteen patients affected by rrmHR-NBL were treated with high-activity
RESULTS
RESULTS
The cumulative
CONCLUSIONS
CONCLUSIONS
Our experience demonstrated feasibility of high activity therapy of
Identifiants
pubmed: 35111625
doi: 10.21037/qims-21-548
pii: qims-12-02-1299
pmc: PMC8739146
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1299-1310Informations de copyright
2022 Quantitative Imaging in Medicine and Surgery. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/qims-21-548). The authors have no conflicts of interest to declare
Références
Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):234-241
pubmed: 27663238
Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1567-1575
pubmed: 30838430
Eur J Nucl Med Mol Imaging. 2008 May;35(5):1039-47
pubmed: 18274745
Phys Med Biol. 2016 Jun 7;61(11):4316-26
pubmed: 27200493
Cancer Biother Radiopharm. 2005 Apr;20(2):195-9
pubmed: 15869455
Med Phys. 2015 Jul;42(7):3969-78
pubmed: 26133597
IEEE Trans Med Imaging. 1991;10(3):408-12
pubmed: 18222843
J Nucl Med. 2005 Jun;46(6):1023-7
pubmed: 15937315
Med Phys. 2013 Oct;40(10):102504
pubmed: 24089925
Health Phys. 2003 Sep;85(3):294-310
pubmed: 12938720
Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1238-50
pubmed: 20411259
Biol Blood Marrow Transplant. 2009 Sep;15(9):1077-85
pubmed: 19660720
EJNMMI Phys. 2020 Mar 6;7(1):15
pubmed: 32144574
Cancer Biother Radiopharm. 2002 Oct;17(5):535-43
pubmed: 12470423
J Clin Oncol. 2017 Aug 1;35(22):2580-2587
pubmed: 28471719
Phys Med Biol. 2016 Mar 21;61(6):2532-51
pubmed: 26948833
J Nucl Med. 1999 Feb;40(2):37S-61S
pubmed: 10025848
Pediatr Blood Cancer. 2013 May;60(5):879-84
pubmed: 23024113
J Nucl Med. 2001 Nov;42(11):1713-21
pubmed: 11696644
Cancer Biother Radiopharm. 2007 Feb;22(1):105-12
pubmed: 17627418
J Clin Oncol. 2011 Aug 20;29(24):3286-92
pubmed: 21768459
Eur J Cancer. 2014 Mar;50(4):801-15
pubmed: 24333097
J Clin Oncol. 2007 Mar 20;25(9):1054-60
pubmed: 17369569
Children (Basel). 2018 Oct 31;5(11):
pubmed: 30384486
J Nucl Med. 2009 Sep;50(9):1518-24
pubmed: 19713562
J Nucl Med. 2005 May;46(5):899-900; author reply 901
pubmed: 15872367
J Clin Oncol. 2006 Jan 20;24(3):500-6
pubmed: 16421427
Med Phys. 2007 Nov;34(11):4285-92
pubmed: 18072493